Abstract: A method for determining a configuration setting of a source of ionizing radiation reducing a radiation dose absorbed by a patient and a practitioner in a medical operating room during a procedure. Prior to the procedure a database of maps of simulated propagation and scattering of ionizing radiation in a model of the medical operating room is obtained for different configuration settings. During the procedure, a position of the practitioner is determined. After determining a set of configuration settings of the source enabling the production of an image of a target anatomical structure a radiation dose absorbed by the patient and the practitioner is determined using the maps from the database. A recommended configuration setting for which a combined radiation dose is reduced is then outputted.

Abstract: A polyester polyol of formula produced by a first polycondensation (a) of a sugar alcohol Z in C3 to C8 and two diacids Y and Y? which are the same or different in C4 to C36, and a second polycondensation (b) of the product produced in (a) with two diols X and X? which are the same or different in C2 to C12, the polymer including such a polyester polyol. Also, a method for producing the polyester polyols and the use thereof in foams, adhesives, coatings or elastomers of polyurethane or polyisocyanurate.

Abstract: The present invention relates to a method for capturing a molecular target present in the aqueous phase of a water-in-oil emulsion, said method being based on the use of a binding system comprising (a) a surfactant bearing a functional moiety on its hydrophilic head group and (b) a chemoprobe that acts as a molecular staple between the functionalized surfactant and the molecular target and comprises at least two distinct domains namely (i) at least one capture moiety which is able to specifically bind the molecular target and (ii) at least one binding domain which is able to interact with the functional group of the surfactant through covalent or non-covalent interactions, directly or through a binding intermediary.

Abstract: An optical guide for a near-eye display device includes a first guide element having a light input zone and a second guide element having an output zone. The first guide element is superimposed on the second guide element. The optical guide also includes an optical coupling system between the first guide element and the second guide element, and the first and second guide elements have, on the first part of their length, a mutual spacing so as to delimit a thin layer of air between said guide elements extending between a first longitudinal end of the guide elements and the optical coupling system. The optical coupling system, located at a second longitudinal end of the first and second guide elements, includes a single-piece portion of the guide elements, associated with an optical reflection member to propagate the beams of light from the input zone toward the output zone.

Abstract: A protective helmet includes an inner cap, an outer cap and a decoupling layer capable of allowing the outer cap to rotate relative to the inner cap about any axis of rotation in the event of an impact. At least one spherical surface is completely contained in the decoupling layer. The helmet includes a fastening strap attached at two opposing points of the inner cap without any mechanical connection with the outer cap. The strap is intended to fasten the helmet to the head of the wearer. The helmet includes a fastening frame attached to the inner cap, and the strap is attached to the inner cap by the fastening frame.

Abstract: The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.

Abstract: A rigid foam or composition allowing a rigid foam to be obtained made from polyurethane and/or polyisocyanurate. The rigid foam or composition includes polyols selected from polyester polyols and polyether polyols; the polyols include: 5 to 50% of a polyester polyol A by weight relative to the total weight of the polyols; and a polyol B selected from polyester polyols B and polyether polyols B. The polyester polyol A is of general formula Rx-Ry-Z-Ry?-Rx? in which Z is a C3 to C8 alcohol sugar chosen from glycerol, sorbitol, erythritol, xylitol, araditol, ribitol, dulcitol, mannitol and volemitol. Ry and Ry? are diesters of formula —OOC—Cn-COO— in which n is between 2 and 34, and Rx and Rx? are identical or different C2 to C12 monoalcohols.

Abstract: The invention relates to compounds, pyridine derivatives, and pharmaceutical 10 compositions containing same for use in the treatment of pain. It also relates to specific compounds, compositions comprising the same and uses thereof, in particular in the treatment of pain.

Abstract: A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.

Abstract: The present invention relates to a vector which comprises a nucleic acid sequence encoding for the frataxin (FXN) gene for use in the prevention and treatment of neurological phenotype associated with Friedreich ataxia in a subject in need thereof.

Abstract: The present invention concerns an oligonucleotide-functionalized hydrophobic polymer nanoparticle and method of its preparation. Said nanoparticle is a dye-loaded polymeric nanoparticle, and being functionalized by: (a) target-specific oligonucleotides, and/or (b) non-specific oligonucleotides.

Abstract: The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.

Abstract: Some embodiments are directed to optical conductors comprising one or more fibrillar organic supramolecular species including an association of triarylamines, methods of preparation and applications thereof as optical and plasmonic waveguides.

Abstract: A process for producing a five-membered polycycloaliphatic carbonate including a step of reacting a suspension of a powdered sugar alcohol within a carbon dioxide source and a catalyst compound which is soluble in the carbon dioxide source at the reactional temperature. The invention also concerns a process for producing non-isocyanate polyurethane and/or a polycarbonate and/or polyethers including the step of obtaining a five-membered polycycloaliphatic carbonate according to the process for producing a five-membered polycycloaliphatic carbonate.

Abstract: The invention relates to a method for producing a cocrystal of at least two compounds by means of instantaneous evaporation or flash evaporation, for example for the production of cocrystals in the fields of energetic materials, pharmaceutical compounds, phytopharmaceutical compounds, ferroelectric materials, non-linear response materials or bioelectronic materials.

Abstract: The invention relates to cationic siRNAs, characterized in that they are double-stranded RNA fragments, grafted to the ends of which are oligocations, the number of cationic charges grafted being comparable to or greater than that of the anionic charges carried by the internucleoside phosphates of the RNA strands.

Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.

Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).

Abstract: The balloon includes a pouch formed of a sealed wall delimiting an internal space, and a valve for filling the internal space with a fluid, capable of being occluded after filling the internal space. The pouch delimits a fluid-draining orifice opening into the internal space. The balloon further includes an occluding ball that occludes the draining orifice. The occluding ball can be spherical or polyhedral, and be capable of releasing the draining orifice under the effect of a magnetic field, so as to enable the at least partial drainage of the fluid contained in the internal space. The occluding ball is movable along at least two distinct axes in relation to the pouch.

Abstract: A magnetic operational amplifier having a differential stage includes a first magnetic field effect transistor MAGFET and a differential signal conditioner, the differential signal conditioner including a load stage, a differential input pair connected to the load stage and a biasing current source connected to the differential input pair; the magnetic field effect transistor MAGFET being connected to the load stage as a second differential input pair and the differential signal conditioner including a second biasing current source connected to the magnetic field effect transistor MAGFET.